USPTO serial 97537482
PEAK DV
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 2, 2024
- Examiner
- DIBLE, JONATHON I
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PEAK DV?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Allentown, NJ, US
Allentown, NJ, US
Allentown, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Neil M. Barnes
Neil M. Barnes Neo IPPO Box 52546Durham, NC 27717United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Software as a service (SAAS) services featuring software using artificial intelligence for use in pharmaceutical drug development, metadata tagging in the fields of healthcare and pharmaceuticals, identifying biomarkers, identifying mutations, identifying comorbidities, identifying side effects of drugs, identifying efficacy of drugs, identifying clinical study designs, identifying pharmacokinetics (PK), identifying study arms for clinical studies, identifying patient characteristics, identifying disease characteristics, identifying labs, identifying resistance markers, identifying disease therapies, vaccine development, diagnostics development in the fields of healthcare and pharmaceuticals, analyzing clinical data in the fields of healthcare and pharmaceuticals, analyzing clinical data in healthcare databases, health economics and outcomes research (HEOR) in the fields of healthcare and pharmaceuticals, conducting clinical trials in the fields of healthcare and pharmaceuticals, accessing and analyzing competitive intelligence information in the fields of healthcare and pharmaceuticals, organizing, managing, and tracking data during development of a drug and over the life of a drug, creating and updating clinical guidelines in the fields of healthcare and pharmaceuticals, personalizing treatment options in the fields of healthcare and pharmaceuticals, and patient identification in the fields of healthcare and pharmaceuticals; Platform as a service (PAAS) services featuring software platforms using artificial intelligence for use in pharmaceutical drug development, metadata tagging in the fields of healthcare and pharmaceuticals, identifying biomarkers, identifying mutations, identifying comorbidities, identifying side effects of drugs, identifying efficacy of drugs, identifying clinical study designs, identifying pharmacokinetics (PK), identifying study arms for clinical studies, identifying patient characteristics, identifying disease characteristics, identifying labs, identifying resistance markers, identifying disease therapies, vaccine development, diagnostics development in the fields of healthcare and pharmaceuticals, analyzing clinical data in the fields of healthcare and pharmaceuticals, analyzing clinical data in healthcare databases, health economics and outcomes research (HEOR) in the fields of healthcare and pharmaceuticals, conducting clinical trials in the fields of healthcare and pharmaceuticals, accessing and analyzing competitive intelligence information in the fields of healthcare and pharmaceuticals, organizing, managing, and tracking data during development of a drug and over the life of a drug, creating and updating clinical guidelines in the fields of healthcare and pharmaceuticals, personalizing treatment options in the fields of healthcare and pharmaceuticals, and patient identification in the fields of healthcare and pharmaceuticals | ACTIVE | Nov 14, 2022 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 24, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 24, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 2, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 2, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 28, 2024 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Feb 27, 2024 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Feb 24, 2024 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Feb 24, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 1, 2024 | IUAF | USE AMENDMENT FILED | — |
| Feb 1, 2024 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Dec 12, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 17, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 17, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 11, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 1, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 31, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 31, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 27, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 27, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 27, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 3, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 3, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 3, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 23, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 28, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 9, 2022 | NWAP | NEW APPLICATION ENTERED | — |